← back to search

Jonathan G. Howlett

Calgary Laboratory Services · CA
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, and Diabetes Treatment and Management.
h-index
66
citations
23,884
works
311
NIH funding
primary concept
Medicine
email

Recent publications

STICH3C: Rationale and Study Protocol
Circulation Cardiovascular Interventions 2023cited by 37position: middledoi
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial
The Lancet 2022cited by 170position: middledoi
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
European Heart Journal 2022cited by 35position: middledoi
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Canadian Journal of Cardiology 2021cited by 288position: middledoi
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure
JAMA Cardiology 2021cited by 104position: middledoi
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
JACC Heart Failure 2021cited by 49position: middledoi
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
New England Journal of Medicine 2020cited by 637position: middledoi
Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children
Canadian Journal of Cardiology 2020cited by 583position: middledoi
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
JAMA 2020cited by 529position: middledoi
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
European Heart Journal 2020cited by 211position: middledoi
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
European Heart Journal 2020cited by 194position: middledoi
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
European Heart Journal 2020cited by 133position: middledoi
Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison with Contemporary Clinical Trials
European Journal of Heart Failure 2020cited by 64position: middledoi
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine 2019cited by 6,746position: middledoi
Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Canadian Journal of Cardiology 2018cited by 583position: middledoi
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
Canadian Journal of Cardiology 2017cited by 685position: middledoi
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Canadian Journal of Cardiology 2017cited by 322position: middledoi
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Canadian Journal of Cardiology 2016cited by 469position: middledoi
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Canadian Journal of Cardiology 2015cited by 694position: middledoi
The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Canadian Journal of Cardiology 2014cited by 270position: middledoi
The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Canadian Journal of Cardiology 2013cited by 166position: middledoi
The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy
Canadian Journal of Cardiology 2012cited by 266position: middledoi
The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure
Canadian Journal of Cardiology 2012cited by 209position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John J.V. McMurray · University of Glasgow4 papers (2020–2022)Scott D. Solomon · Harvard University4 papers (2020–2022)Eileen O’Meara · Montreal Heart Institute3 papers (2020–2022)Eva Gonçalvesová · National Institute of Cardiovascular Diseases2 papers (2021–2022)Silvio E. Inzucchi · Yale University2 papers (2020–2021)Inder S. Anand · University of Minnesota2 papers (2021–2021)Kieran F. Docherty · University of Glasgow2 papers (2020–2021)Brian Claggett · Harvard University2 papers (2021–2022)Stephen B. Heitner · Brigham and Women's Hospital2 papers (2021–2022)Anna Maria Langkilde · AstraZeneca (Brazil)2 papers (2020–2021)John R. Teerlink · University of Glasgow2 papers (2021–2022)Piotr Ponikowski · University of Business in Wrocław2 papers (2020–2021)Pardeep S. Jhund · Harvard University2 papers (2020–2021)G. Michael Felker · Duke University2 papers (2021–2022)Olof Bengtsson · University of Glasgow2 papers (2020–2021)Marc S. Sabatine · Smart Material (Germany)2 papers (2020–2021)Mikaela Sjöstrand · AstraZeneca (Sweden)2 papers (2020–2021)Lars Køber · Nordsjællands Hospital2 papers (2020–2021)Felipe A. Martínez · Mayo Clinic in Arizona2 papers (2020–2021)Mirta Díez · Instituto Cardiovascular de Buenos Aires2 papers (2020–2021)